MedTrace Logo

Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma

NCT04048343 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2022-06-01

Study results available
· View outcomes & findings →

Summary

This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled severe asthma.

Conditions

Interventions

DRUG

Biological: Experimental: Tezepelumab

Tezepelumab subcutaneous injection every 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Masaharu Shinkai, MD · Tokyo Shinagawa Hospital Medical Corporation Association, Japan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-10
Primary Completion
2021-03-18
Completion
2021-03-18
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04048343 on ClinicalTrials.gov